Attitudes Toward Vaccines in the Chronic Conditions Community: Survey Highlights

Novel AD therapies targeting OX40, IL-13, IL-36, IL-22, and IL-2 pathways show promise for disease modification and extended dosing intervals in phase 2-3 trials.

Treatment goals for atopic dermatitis among youth are diverse, emphasizing the need for tailored approaches based on age and disease severity, a new study suggests.

Remibrutinib is the first oral BTK inhibitor for chronic spontaneous urticaria, with a dual mechanism of action that blocks 2 key autoimmune mechanisms.

Patient Care tapped the rich trove of research and expert perspectives from the Revolutionizing Atopic Dermatitis 2025 conference to create a snapshot of the AD care of the future.

The findings highlight rezpegaldesleukin's novel broad-based Treg mechanism, suggesting it may be a potent option with potential for disease modification in atopic dermatitis.

EADV 2025: Phase 3 ROCKET-SHUTTLE results showed the T-cell rebalancing therapy significantly improved AD signs and symptoms in treatment-experienced adults.